Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Aug 6, 2007

J&JPRD to Apply Melior’s In Vivo Models

  • Melior Discovery’s theraTRACESM indications discovery platform will be used to identify possible new indications for multiple Johnson & Johnson Pharmaceutical Research & Development (J&JPRD) drug candidates.

    The theraTRACE platform is a multiplexed set of integrated in vivo models that systematically test the potential efficacy of compounds across a large number of disease models. It reduces the time, amount of test compound, and number of test subjects needed while also reducing the number of false positive results, according to the companies.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »